Aravive (NASDAQ:ARAV) Rating Lowered to Strong Sell at ValuEngine
Several other equities research analysts have also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $31.00 target price (up from $18.00) on shares of Aravive in a research note on Wednesday, November 20th. Wedbush upped their target price on Aravive from $12.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 20th. Robert W. Baird upgraded Aravive from a “neutral” rating to an “outperform” rating in a research note on Monday. Piper Jaffray Companies increased their price target on Aravive from $15.00 to $36.00 and gave the company an “overweight” rating in a research note on Tuesday, November 19th. Finally, Zacks Investment Research cut Aravive from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Aravive currently has a consensus rating of “Buy” and a consensus target price of $25.69.
NASDAQ ARAV opened at $10.65 on Tuesday. The business has a fifty day moving average price of $7.35 and a two-hundred day moving average price of $6.51. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.59 and a quick ratio of 7.59. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $15.62. The stock has a market capitalization of $108.86 million, a PE ratio of -1.00 and a beta of 2.35.
In other news, CEO Jay Shepard sold 4,004 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $6.82, for a total value of $27,307.28. 39.80% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Artal Group S.A. lifted its stake in shares of Aravive by 20.0% in the 2nd quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after acquiring an additional 51,197 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Aravive by 5.8% in the 2nd quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after acquiring an additional 9,544 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Aravive by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after acquiring an additional 7,200 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Aravive by 13.8% in the 2nd quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after acquiring an additional 18,017 shares during the last quarter. Institutional investors own 30.85% of the company’s stock.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Featured Article: What is the Ex-Dividend Date in Investing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.